428 related articles for article (PubMed ID: 37822927)
21. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
22. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
23. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
25. [Construction of Lung Adenocarcinoma Prognosis Model and Drug Sensitivity Analysis Based on Cuproptosis Related Genes].
Sun J; Zhang H; Liu H; Dong Y; Wang P
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):591-604. PubMed ID: 37752539
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-Related Gene
Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
[TBL] [Abstract][Full Text] [Related]
28. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
29. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
31. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
32. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma.
Yan X; Zheng W; Xu FS; Chang HL; Zhang Y; Zhang ZY; Zhang YH
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2024-2050. PubMed ID: 38497885
[TBL] [Abstract][Full Text] [Related]
35. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
36. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
Liu L; Wang Q; Zhou JY; Zhang B
J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
39. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
40. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]